专家警告:更新式GLP-1减肥药可能成为全球药品可及性的下一个战场
STAT+: Newer GLP-1 drugs to combat obesity may be the next global battleground over access to medicines, expert warns
伦敦政治经济学院教授Ken Shadlen指出,更新式GLP-1减肥药可能成为低收入国家药品可及性的下一个主要战场。诺和诺德减肥药semaglutide(商品名Wegovy)的低成本仿制药已在部分国家陆续上市,业界正加速研发更有效、副作用更少且给药更便捷的新一代药物。专家称这虽有望惠及更多患者,却也引发对未来药品准入公平性的担忧。
![]()
By Ed Silverman
Nov. 16, 2026
Pharmalot Columnist, Senior Writer
Over the past few months, lower-cost generic versions of the blockbuster GLP-1 drug semaglutide, which is sold as Wegovy by Novo Nordisk for combating obesity, started to become available in some countries and will soon arrive in still others. Meanwhile, the pharmaceutical industry is racing to develop newer GLP-1 medicines that, to varying degrees, are forecast to be more effective, cause fewer side effects, and are easier to administer.
On one hand, these developments suggest more people than ever before may find needed help for losing weight. But there is another possibility: Obesity medications may become the next big battleground over access to medicines in lower-income countries, according to Ken Shadlen, a London School of Economics professor who studies the politics of pharmaceutical and health regulation. We spoke with him about the looming challenges that may soon confront drugmakers, governments, and patients. This is an edited version of our conversation.
You’re making a provocative point, although newer GLP-1 drugs that are better or easier to use or safer are not yet here. Why is it important to raise the issue now?
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
来源:STAT 主站 · statnews.com